PACIFIC-2
PACIFIC-2 asked whether starting durvalumab during chemoradiotherapy, rather than after it, would help people with stage III lung cancer; it did not, so the sequence established by the original PACIFIC trial stands.
Overview
PACIFIC established durvalumab given after chemoradiotherapy as the standard for unresectable stage III non-small-cell lung cancer. PACIFIC-2 tested the more aggressive schedule of starting durvalumab at the same time as platinum-based chemoradiotherapy and continuing it afterwards, against placebo, in 328 patients. The primary endpoint was progression-free survival.
The trial did not show a statistically significant improvement in progression-free survival, and more patients in the durvalumab arm stopped treatment early for adverse events. Consolidation after chemoradiotherapy therefore remains the way durvalumab is used in this setting.
Similar pages
not linked directly; found by shared links- TrialCALLA
Shares Durvalumab, Cisplatin, AstraZeneca and the tag subtype-trials.
- TrialKEYNOTE-407
Shares Lung cancer (all types), Carboplatin, Non-small-cell lung cancer and the tag subtype-trials.
- TrialDESTINY-Lung01
Shares Lung cancer (all types), AstraZeneca, Non-small-cell lung cancer and the tag subtype-trials.
- TrialCheckMate 227
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
- TrialCHRYSALIS
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
- TrialCOG ACNS0332
Shares Cisplatin, Carboplatin and the tag subtype-trials.
- TrialORATOR
Shares Cisplatin and the tag subtype-trials.
- TrialKEYNOTE-412
Shares Cisplatin and the tag subtype-trials.